Graves T
Department of Pharmacy, Emory University Hospital, Atlanta, Georgia 30322.
Pharmacotherapy. 1992;12(4):337-45.
Up to 30% of patients receiving chemotherapy experience uncontrolled nausea and vomiting despite pharmacotherapeutic advances. Currently marketed agents used to treat these symptoms are compared. Dose escalation of these agents may improve response rates. Recent focus has been on a new class of antiemetics, the serotonin antagonists. Ondansetron, currently the only serotonin antagonist with Food and Drug Administration approval for treatment of chemotherapy-induced emesis, demonstrates the efficacy and potential advantages of this class of antiemetics.
尽管药物治疗取得了进展，但接受化疗的患者中仍有高达30%会出现无法控制的恶心和呕吐。对目前用于治疗这些症状的上市药物进行了比较。增加这些药物的剂量可能会提高缓解率。最近的研究重点是一类新型止吐药，即血清素拮抗剂。昂丹司琼是目前唯一获得美国食品药品监督管理局批准用于治疗化疗引起的呕吐的血清素拮抗剂，它证明了这类止吐药的疗效和潜在优势。
